Status:
COMPLETED
Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
American Diabetes Association
National Institutes of Health (NIH)
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
30-55 years
Phase:
NA
Brief Summary
This study will evaluate the effects of impaired blood flow regulation on exercise. It will also determine whether the effects are more important in the heart or in the skeletal muscle tissue during e...
Detailed Description
The investigators have found that persons with type 2 diabetes have an impaired ability to perform exercise even without clinically apparent complications. The reasons for this marked abnormality are ...
Eligibility Criteria
Inclusion
- Men and women with uncomplicated Type 2 Diabetes
- Healthy men and women without Type 2 Diabetes
- Patients with Type 2 Diabetes may be taking metformin or sulfonylurea drugs to treat diabetes
- Persons with history of hypercholesteremia if controlled with statins and/or diet
- Patients who are moderately overweight (BMI 25-37.5)
- Must be sedentary (defined as regular exercise \< 2 times a week at a low to moderate level).
- Patients with Hemoglobin A1c (HBA1C) \<8%
- Patients between the ages of 30 to 55 years
- Premenopausal women.
- Former smokers who have quit smoking for at least one year
- Absence of comorbid conditions
- Mild neuropathy is O.K. as long as it will not hamper exercise performance.
- Resting systolic blood pressure (SBP) \< 140, Resting diastolic blood pressure (DBP) \< 90
- Total Cholesterol \< 205 Triglycerides \< 250 low density lipoprotein (LDL) \< 130
- Control subjects with a normal A1C and fasting glucose
Exclusion
- People with T2DM taking oral medications, other than metformin or sulfonylurea drugs to control their diabetes.
- Persons treated with insulin will be excluded
- People who are currently smoking or have not quit for at least one year
- Controls who have immediate family history of T2DM
- Peri-menopausal or post-menopausal women.
- Peripheral neuropathy
- Total cholesterol \> 205
- Regional wall motion abnormalities
- LV wall thickness ≥1.1 cm
- Decreased contractility (fractional shortening \<30%)
- Ischemic heart disease (abnormal resting or exercise ECG)
- Presence of angina that would limit exercise performance
- Pulmonary problems that would limit exercise performance
- Systolic blood pressure \>140 mmHg at rest or \>250 mmHg with exercise or diastolic pressure \>90 mmHg at rest or \>105 mmHg with exercise
- Persons with autonomic insufficiency, assessed by measuring variation in RR intervals with cycled breathing and by presence of a \>20 mm fall in upright blood pressure without a change in heart rate
- Proteinuria (urine protein \>200 mg/dl) or a creatinine \> 2 mg/dl
- Renal disease
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00786019
Start Date
May 1 2008
End Date
October 1 2011
Last Update
July 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver
Aurora, Colorado, United States, 80045